Preclinical and phase 1 studies have demonstrated promising antitumoral activity of botensilimab/balstilimab in “cold tumors” that have been historically unresponsive or resistant to immunotherapy.48,49 The phase 2 ARCITECT trial (NCT05928806) is currently examining the combination of botensilimab/balstilimab (anti-CTLA-4/anti-PD1) for first-line treatment of metastatic ccRCC.50 Here, CTLA4 is linked to nonpapillary renal cell carcinoma.